Evaluating the safety and efficacy of Unani formulations in Psoriasis

A Randomized, Parallel Group, Open Label, Active Controlled Clinical Study to evaluate the Safety and Efficacy of Safuf-i-Chobchini and Ravghan-i-R ?l in the Management of Taqashshur al-Jild (Psoriasis) - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/06/068896

Enrollment

Registered

2024-06-13

Start date

Unknown

Completion date

Unknown

Last updated

2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L409- Psoriasis, unspecified

Interventions

Intervention1: Safuf-i-Chobchini (Oral) and Ravghan-i-R ?l (Topical): 1.Safuf-i-Chobchini: Dosage form: Safuf (powder) Dose : 5 gms Twice daily after meals with water Duration : 08 Weeks Mode of admi

Eligibility

Inclusion criteria

Inclusion criteria: Patients of any sex aged between 18-60 years of age, Patients clinically diagnosed with Taqashshur al-Jild (Psoriasis), Psoriasis area severity index (PASI) =10%.

Exclusion criteria

Exclusion criteria: Pregnant or Lactating Women, Significant Pulmonary/Cardiovascular/ Hepato-renal Dysfunction, Known cases of Immunocompromised states (HIV/ AIDS, etc.)/ Malignancies, Patients with Psoriatic arthritis, Erythrodermic psoriasis.

Design outcomes

Primary

Measure	Time frame
Change in mean PASI Score from baseline to 2nd,4th and 8th week post treatmentTimepoint: 56 DAYS	—

Secondary

Measure	Time frame
Change in DLQI assessment will be done at 2nd,4th & 8th week post treatmentTimepoint: 56 DAYS	—

Countries

India

Contacts

Public ContactDr Sadiya Siddiqua

National Research Institute Of Unani Medicine For Skin Disorders

aarzu763@gmail.com9032519286

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026